Company profile · free preview

CAMP4 Therapeutics

CAMP · Updated 10/24/2026

Revenue

$3.5M

Fiscal 2025

Net income

(80.4M)

Fiscal 2025

Free cash flow

(29.8M)

Fiscal 2025

Net cash / (debt)

—

Fiscal 2025

Five-year financials

Fiscal year20252024
Revenue$3.5M$652000
Net income(80.4M)(51.8M)
Diluted EPS——
Operating cash flow(29.6M)(45.6M)
Free cash flow(29.8M)(46.0M)
Cash$109.5M$64.0M
Total debt——

Where the cash went

Cumulative, fiscal 2024–2025, straight from the reported cash-flow statements.

Reinvested in capex

—

of operating cash flow

Returned to owners

—

of free cash flow (buybacks + dividends)

Diluted share count

—

change 2024–2025

Capital expenditure $720000Bar width = share of $720000 (spending exceeded operating cash flow)
Operating cash flow($75.1M)
Capital expenditure($720000)
Free cash flow($75.8M)
Share buybacks—
Dividends paid—
Acquisitions (net)—
Net debt issued / (repaid)—
Stock-based compensation (non-cash)—

"—" means a year didn't report that line, so no total is shown rather than an estimate.

SEC filings

No filings stored yet.

Ask anything about CAMP4 Therapeutics's filings

"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.

Start researching free

More companies